The 2026 NDAA 'piggyback' passage looms: Revised Biosecurity Act avoids direct 'naming' – could the immediate impact be mitigated?

① The rules for considering the 2026 NDAA, which includes the revised Biosecurity Act, have been passed by a vote in the U.S. House of Representatives and may soon be put to a vote in the House; ② The revised Biosecurity Act removes direct references to specific Chinese companies and includes a relatively long grace period; ③ Legal experts believe that the likelihood of the Biosecurity Act being successfully attached to the NDAA is high, but its impact will be limited.

cls.cnDec 10 15:39

Jin10 Global Financial Morning Briefing | December 9, 2025

Trump is set to issue an executive order establishing a unified rule for AI, Russia will impose restrictions on gold bar exports starting next year, a 7.5-magnitude earthquake occurred near the eastern coast of Japan's Honshu region, and the Political Bureau of the Central Committee of the Communist Party of China held a meeting... What major events took place around the world overnight and this morning?

Golden10 DataDec 9 06:51

Intelligent Stock Connect HKEX Ratio Anomaly Statistics | December 8

According to Zhitong Finance APP, based on the disclosed data as of December 5, 2025, the companies with the largest increase in the proportion of shares held via Stock Connect were Southern Port Technology (03442), Lion Teng Holdings (02562), and Ji Hong Co., Ltd. (02603), increasing by 1.35%, 1.19%, and 0.75%, respectively. The companies with the largest decrease in the proportion of shares held via Stock Connect were Haotian International Construction & Investment (01341), Longpan Technology (02465), and Weimeng Group (02013), decreasing by -0.93%, -0.83%, and -0.59%, respectively.

Zhitong FinanceDec 8 08:36

19+114! The National Medical Insurance and Commercial Insurance 'Dual Catalog' Released: Success Rate of Innovative Drug Negotiations Increases to 88%

①The 2025 National Medical Insurance Drug Catalogue successfully added 114 new drugs, of which 50 are Class I innovative drugs. The overall success rate was 88%, significantly higher than the 76% in 2024; ②Among the 19 drugs included in the inaugural commercial insurance innovative drug directory are not only cancer treatments such as CAR-T, but also rare disease treatments for neuroblastoma and Gaucher's disease.

cls.cnDec 7 18:03

Nearly half of the newly added drugs are Class 1 new drugs! The 2025 National Reimbursement Drug List results unveiled: All five CAR-T therapies achieve commercial insurance breakthroughs, marking the entry of innovative drug payment into the 'value era'.

①A total of 114 drugs have been included in the National Medical Insurance Drug Catalog, among which there are 50 Class I new drugs; Hengrui and Innovent have emerged as major beneficiaries. ②Nineteen innovative drugs have been incorporated into the commercial insurance innovative drug catalog, with all five CAR-T therapies successfully negotiated. Multinational companies such as Pfizer and Eli Lilly and Co have also achieved significant gains. ③Support for genuine innovation has become the main theme, with the industry paying close attention to the implementation of the commercial insurance innovative drug catalog.

cls.cnDec 7 13:57

Intelligent Connectivity HKEX Stock Connect Proportion Anomaly Statistics | December 5

Intelligent Channel HKEX Connect Proportion Anomaly Statistics | December 4, 2025

Zhitong FinanceDec 5 08:36